NVO Stock Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for NVO from our risk checks.
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.124.53 |
| 52 Week High | kr.138.28 |
| 52 Week Low | kr.75.56 |
| Beta | 0.20 |
| 1 Month Change | -6.29% |
| 3 Month Change | 15.79% |
| 1 Year Change | 50.92% |
| 3 Year Change | 235.52% |
| 5 Year Change | 414.91% |
| Change since IPO | 68,606.59% |
Recent News & Updates
Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Recent updates
Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
Sep 22Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Aug 30Novo Nordisk: Denmark's Coca-Cola
Jul 25The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
Jul 11Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
Jun 23Novo Nordisk: Dominating In Diabetes And Obesity
Jun 05Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity
May 23Novo Nordisk: Attractive Market But Likely No Margin Of Safety
Feb 15Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg
Feb 07Novo Nordisk FY 2022 Earnings Preview
Jan 31Novo Nordisk says FDA updated label for oral diabetes therapy Rybelsus
Jan 13Shareholder Returns
| NVO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.3% | -2.2% | -3.7% |
| 1Y | 50.9% | 11.6% | 20.5% |
Return vs Industry: NVO exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: NVO exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVO has not had significant price volatility in the past 3 months.
Volatility Over Time: NVO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 63,845 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market cap | US$554.50b |
| Earnings (TTM) | US$11.94b |
| Revenue (TTM) | US$33.13b |
46.5x
P/E Ratio16.7x
P/S RatioIs NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | kr.232.26b |
| Cost of Revenue | kr.35.77b |
| Gross Profit | kr.196.50b |
| Other Expenses | kr.112.81b |
| Earnings | kr.83.68b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 18.76 |
| Gross Margin | 84.60% |
| Net Profit Margin | 36.03% |
| Debt/Equity Ratio | 20.0% |
How did NVO perform over the long term?
See historical performance and comparison